About Us

First, it should be stated that Dr. Weisenthal is not the author of this website, although some - but not all - of the quotes reproduced in larger font on the various pages are excerpted from letters and emails written by Dr. Weisenthal, mainly to colleagues. 

The voice you “hear” on this website is principally that of David Weisenthal, Dr. Weisenthal’s brother, formerly a senior manager and corporate officer at several oncology-focused biotech and laboratory companies and now fully-committed to supporting Dr. Weisenthal’s research.

Dr. Weisenthal’s staff includes 5 laboratory technicians, a laboratory manager, and two administrative coordinators.

In other words, this discovery comes from a small, family-operated cooperative endeavor whose focus, until recently, has been exclusively upon cancer.  We are not a large, richly-resourced pharmaceutical, biotech, or academic institution with an established presence in the field of cardiovascular disease.  This largely explains why the MCED work described here, despite its importance, has achieved little visibility and no grant support whatsoever.  

Also, it is a convention in science to use the word “we” when describing one’s work, especially when directing a staff.  However, it should be noted that the discovery of MCED and all subsequent discoveries and insights related to it originate exclusively with Larry Weisenthal, M.D., Ph.D..  

Dr. Weisenthal is a physician who is board-certified in internal medicine and medical oncology.  In addition to his medical degree and oncology specialty, Dr. Weisenthal also holds a separate Ph.D. degree in pharmacology research and an academic appointment as Associate Clinical Professor of Medicine at University of California Irvine.

Dr. Weisenthal owns a laboratory-based medical oncology practice, which he founded in 1992.  His work involves helping cancer patients to receive personalized chemotherapy treatments that offer the highest probability of clinical benefit.  In this work, he uses a laboratory test called the DiSC assay, which he invented himself.  His test has been called the “gold standard” by colleagues in his field.  It has been used to guide the treatments of thousands of cancer patients worldwide. (www.weisenthalcancer.com)

In addition, Dr. Weisenthal conducts innovative cancer research and regularly publishes his findings in medical journals and presents at medical meetings and symposia.

Curriculum Vitae

Larry Mark Weisenthal, M.D., Ph.D.

16512 Burke Lane

Huntington Beach, CA  92647



Current Positions

Medical and Laboratory Director

Weisenthal Cancer Group

Huntington Beach, CA


Research Director

MCED VasoCell

Huntington Beach, CA


Clinical Associate Professor of Medicine

Department of Medicine, Hematology/Oncology

University of California, Irvine

Irvine, CA


Certification Boards

American Board of Internal Medicine

Certified, Medical Oncology

Medical License 

California G 041204

Undergraduate Education    

University of Louisville

Louisville, KY

Undergraduate chemistry major

B.A. equivalent - entered medical school after 3 years

Medical Education

University of Michigan

Ann Arbor, MI


Graduate Education

University of Michigan

Ann Arbor, MI

Ph.D. Pharmacology

Laboratory of Raymond W. Ruddon, MD, PhD


Post Graduate Education


Internal Medicine

University Hospital

Ann Arbor, MI

Post-Doctoral Fellowship

Medical Oncology Clinical Associate

National Cancer Institute, Bethesda, MD

Medicine Branch/COP/DCT/NCI


Post-Doctoral Research

National Cancer Institute / National Institutes of Health

Bethesda, MD:

Laboratory of Marc E. Lippman, MD

Military Service

U.S. Public Health Service

Surgeon Grade (Lt. Commander) 

Positions Held 

Instructor (Pharmacology),

University of Michigan             

Staff Physician, Section Hematology/Oncology,

Veterans Administration Medical Center

Long Beach, CA       

Assistant Professor in Residence

Department of Medicine

University of California Irvine

Irvine, CA

Clinical Investigator

Veterans Administration Central Office

Career Development Program

Long Beach, CA

Associate Professor in Residence

Department of Medicine

University of California Irvine

Irvine, CA   

Associate Adjunct Professor

Department of Medicine

University of California Irvine

Irvine, CA

Founder, Founding Corporate Director, Laboratory Director, Vice-President for Scientific Affairs

Oncotech, Inc.

Irvine, CA

Government Service

Advisory/Site Visit Committee for National Cancer Institute

Cell Culture New Drug Screening Program

National Oncology Reviewer

Veterans Administration National Research Advisory Group


Please follow this link to view Dr. Weisenthal’s bibliography.

Biographical Sketch

  1. Larry Weisenthal M.D., Ph.D. received his undergraduate education at the University of Louisville where he was chosen Outstanding Freshman, Sophomore, and Junior Man, successively, by the faculty in the years he attended. 

  1. After only three years as an undergraduate at Louisville, Dr. Weisenthal received a scholarship to the University of Michigan Medical School, where he earned his M.D. degree.  Also at Michigan, he earned a separate Ph.D. degree, in Pharmacology. 

  1. Following a residency at the University of Michigan Medical Center and board certification in Internal Medicine, Dr. Weisenthal completed a post doctoral fellowship at the National Cancer Institute, in Bethesda, Maryland, where he was Clinical Associate in the Medicine Branch, earning additional board certification in Medical Oncology. 

  1. At this time, he also began a six year term of duty as Lieutenant Commander in the U.S. Public Health Service.

  1. While at the NCI, Dr. Weisenthal began research in the area of Personalized Medicine, ultimately leading to his developing a laboratory test to aid in individualizing chemotherapy for cancer patients based upon anti-tumor activity of candidate drugs against each patient’s own living tumor cells.  Dr. Weisenthal’s test has been called the “gold standard” by researchers in the field.  The test itself and also the “cell death” endpoint upon which it is based (this endpoint was also originated by Dr. Weisenthal) have been adopted by laboratories worldwide, supplanting older, less effective methods. 

  1. Following a cancer research and medical oncology staff appointment at the Long Beach Veteran’s Administration Medical Center, in Long Beach, California, Dr. Weisenthal co-founded Oncotech, a laboratory company focused on helping physicians nationwide to individualize chemotherapy selection for cancer patients.  The company was later acquired by Ecxiqon. 

  1. In 1992, Dr. Weisenthal founded the Weisenthal Cancer Group which combines a commercial laboratory facility in Huntington Beach, California, owned and operated by Dr. Weisenthal, with his laboratory-based medical oncology practice.  Tumor cells obtained through biopsy from individual cancer patients are tested for susceptibility to a wide range of chemotherapy agents.  Dr. Weisenthal then uses information from the laboratory tests to make personalized chemotherapy recommendations to the patients’ cancer physicians.  Dr. Weisenthal’s physician client base is worldwide. 

  1. Dr. Weisenthal holds an academic appointment as Associate Clinical Professor of Medicine at the University of California Irvine. 

  1. He has served on numerous boards and panels including the Editorial Advisory Board of the Journal of the National Cancer Institute and the Advisory Panel to the New Drug Discovery Program of the National Institutes of Health.

  1. He also served and as National Oncology Research Grant Reviewer for the U.S. Veteran’s Administration. 

  1. Dr. Weisenthal has been an invited lecturer at numerous medical meetings, seminars, and symposia in the U.S., Europe, and Asia.   He is author of more than 100 published articles, abstracts, and textbook chapters and is co-editor of an oncology textbook.

Larry Weisenthal, M.D., Ph.D.

New Discoveries in Cancer and Heart Disease

“The discovery of circulating MCED truly is a case of opportunity meeting the prepared mind.  Thirty-five years of full-time cellular research and a fortuitous alignment of circumstances led to the breakthrough.”